(PharmaNewsWire.Com, January 21, 2017 ) Publisher's "Ulcerative Colitis (UC) - Market Insights, Epidemiology and Market Size Forecast-2020" Reports provides an overview of the disease and global market size of the Ulcerative Colitis (UC) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Ulcerative Colitis (UC) from 2010-2020.Ulcerative colitis is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucous. Ulcerative colitis has an incidence of 1 to 20 cases per 100,000 individuals per year, and a prevalence of 8 to 246 per 100,000 individuals. Patients with proctitis or left-sided colitis usually have a more benign course: only 15% progress proximally with their disease, and up to 20% can have sustained remission in the absence of any therapy. Over a decade ago, treatment goals in ulcerative colitis (UC) focused mainly on achieving symptomatic remission.
- Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options. - Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018. - The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2010-2020. - It also provides Market size of Ulcerative Colitis (UC) for United States, EU5 and Japan from 2010 and forecasted Market size to 2020
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: